Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LeICA: Levosimendan in Cardiac Arrest
2024-517279-20-02Phase 2Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of levosimendan in cardiac arrest (SCA) (2 arms), sponsored by Karolinska University Hospital. Primary endpoint: Survival at day 30. Planned start Jun 2025; status: authorised.
02
Drugs
levosimendan
03
Conditions
cardiac arrest (SCA)
Beyond the preview
Go deeper on 2024-517279-20-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517279-20-02.